Skip to content
Peptide research

Tirzepatide

Also known as Mounjaro · Zepbound
Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
FDA-approved

What it is

A dual GIP/GLP-1 receptor agonist used for weight loss and metabolic health. Human evidence is strong: trials show superior weight loss, glycemic control, and heart failure benefit, with softer data on cardiovascular risk. GI side effects are common, and a boxed warning for thyroid tumors in animal studies rules it out for anyone with a history of medullary thyroid cancer or MEN 2. It is FDA-approved, sold as a regulated pharmaceutical, not research-grade.

Read Full record

Studied uses & evidence

Studied uses(8)

  • Superior weight loss

    High

    Multiple large RCTs showed 15-21% weight loss, exceeding semaglutide in a head-to-head trial.

  • Glycemic control

    High

    Multiple phase 3 trials showed HbA1c reductions of 2-2.6 points, beating semaglutide and insulin.

  • T2D prevention

    High

    Single large trial found a 93% reduction in diabetes progression among adults with prediabetes.

Evidence limits

Evidence Level
Level 1 — Strong

600+ PubMed studies. 35,000+ participants across SURPASS (T2DM), SURMOUNT (obesity), SUMMIT (HFpEF), SYNERGY-NASH, SURMOUNT-OSA programs. SURPASS-CVOT alone had 13,000+ patients over 4+ years.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Personal/family history of medullary thyroid carcinoma

    Absolute

    Same thyroid C-cell tumor risk as other incretin-based therapies. Contraindicated in MTC/MEN2.

  • History of pancreatitis

    High

    Monitor closely. Discontinue if pancreatitis suspected.

  • Severe gastroparesis

    High

    Dual GIP/GLP-1 action significantly slows gastric emptying.

General cautions

  • Pregnancy

    Absolute

    Do not use during pregnancy. MHRA guidance recommends stopping tirzepatide at least 1 month before a planned pregnancy.

Risk summary(6)

Risks = level of concern: High · Moderate · Low · Theoretical

  • GI side effects: nausea (13-24%), diarrhea (13-21%), vomiting (6-14%)

    High
  • Boxed warning: thyroid C-cell tumors in animal studies

    Moderate
  • Pancreatitis risk (rare)

    Low
  • Gallbladder disease

    Moderate
  • Potential for hypoglycemia when combined with insulin or sulfonylureas

    Moderate
  • Contraindicated: personal/family history of medullary thyroid carcinoma or MEN 2

    High
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.